Breckenridge Signs New-Product Agreement with PTS Pharma
Breckenridge制药公司. announces today that it has signed a new-product agreement with PTS Pharma, LLC. under which PTS will support a technology transfer to Towa Pharmaceutical Europe, S.L. of a complex "For Suspension" product developed by PTS. The remainder of 发展 and commercialization will be performed at the Towa facility. 根据行业销售数据, the product and its generics had annual sales of approximately $75 million during the twelve months ending February 2022. The companies are actively negotiating and look forward to collaborating on additional complex formulations under the same business model.
Breckenridge制药公司., a subsidiary of Towa Pharmaceutical (Osaka, 日本), partners with manufacturers nationwide and around the world to bring quality, cost-effective generic pharmaceuticals to U.S. 病人. 我们竭诚为客户服务, 准时交货, reliable supply and quality manufacturing, we improve the health and quality of life of the 病人 we and our customers serve.
关于PTS Pharma, LLC:
PTS咨询有限责任公司和PTS制药有限责任公司., 是一个公式开发, 临床试验生产, regulatory services and analytical control laboratory based in Kansas. PTS Consulting is actively involved in regulatory consulting services. PTS Pharma operations include the capability and expertise to develop complex formulations of tablets, 胶囊, 颗粒, 改良剂型, 外用剂型, 栓剂, 电影产品, 解决方案, and suspension formulations and sterile injectables, with involvement in multiple aNDA and NDA filings over the years. The activities are housed in dedicated GMP suites in the facility in Kansas City, USA. PTS Pharma is also involved in active raw material clinical production by fermentation technology processes. The firm was founded in 2003 by Paul Sudhakar, 一个行业资深人士谁是业主, 总统, 也是公司的首席执行官.
For further information, please contact:
Robert Gasparino, Associate Vice 总统 – 可靠的网赌平台
*All brand names and trademarks are the property of their respective owners.